Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Vaccines (Basel)

Title: Vaccines

Publisher: MDPI AG

ISSN: 2076-393X

ISSN (Print): 2076-393X

Publication date (Electronic): Mar 05 2022

Volume: 10

Issue: 3

Affiliations

[1 ] Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.

Article

Publisher Item ID: vaccines10030400

DOI: 10.3390/vaccines10030400

PMC ID: 8954152

PubMed ID: 35335032

SO-VID: 81cff72f-1b06-45e6-8336-96a965182b3a

History

Keywords: vaccination,COVID-19,booster,antibodies,SARS-CoV-2

Data availability:

Keywords: vaccination, COVID-19, booster, antibodies, SARS-CoV-2

Comments

Comment on this article

scite_

Cited by 2

See all cited by